ArticleOncoimmunology2013
EGFR expression levels affect the mode of action of EGFR-targeting monoclonal antibodies.
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
- Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference.Blood neoplasia · 2026Article
- Harnessing the immune system via FcγR function in immune therapy: a pathway to next-gen mAbs.Immunology and cell biology · 2020Review
- Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.Oncoimmunology · 2015Review
- Classification of current anticancer immunotherapies.Oncotarget · 2014Review
- Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.Oncoimmunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidermal growth factor receptor (EGFR) expression levels appear to modulate the efficacy of EGFR-targeting monoclonal antibodies. More specifically, we observed that high EGFR densities negatively affect the effects of EGFR-specific antibodies on EGFR phosphorylation yet exacerbate Fc-mediated tumor-cell killing. These results suggest that the predominant mode of action of EGFR-targeting antibodies depend on EGFR expression levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.